Document is current
Any future updates will be listed below
-
Authors
Bialer, Meir https://orcid.org/0000-0003-2046-4171
Perucca, Emilio https://orcid.org/0000-0001-8703-223X
-
Funding
Funding for this research was provided by:
Hebrew University of Jerusalem
- License Information
-
More Information
Article History
Received: 26 November 2025
Accepted: 26 January 2026
First Online: 1 March 2026
Declarations
:
: This work received no external funding.
: Both authors contributed equally to this work. Both authors have read and approve the final submitted manuscript and agree to be accountable for the work.
: M.B. received consultancy fees from Angelini Pharma, Clexio Therapeutics, Guidepoint, Meditec (Sam On), NeuroSense Therapeutics, Pharma2B, Selene Therapeutics, Shackelford Pharma, and Xenon Pharmaceuticals. E.P. received speaker’s or consultancy fees from Eisai, GRIN Therapeutics, SK Life Science, Sun Pharma, Takeda, UCB Pharma, and Xenon Pharmaceuticals, and royalties from Wiley and Elsevier.
: No datasets were generated or analyzed as part of the present work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
